

INDEX

A

A Mind That Found Itself, 93

Abuse, 229-234, 250, 251, 254-256, 286-289, 335, 340, 342, 368-370, 427-430, 445-449, 455

Acetylcholine, 36, 252, 361, 362

Acetylcholinesterase (AChE), 362

Acute stress disorder, 233, 237

Addictive disorders, 17, 23, 36, 46, 48, 126, 193, 244, 408

Administration on Aging, 370, 371

Adolescent Antisocial Self Report Behavior Checklist, 139

Adult day centers, 363, 371-374, 380

Adverse selection, 20, 420, 423, 426, 429

African Americans, 73, 81-89, 152, 181, 225, 227, 230, 249, 263, 273, 282, 288, 289, 348, 368, 456

Agency for Health Care Policy and Research, 263, 280, 424

Aging, 19, 335-341, 344, 345, 348, 349, 357, 360, 361, 368-372, 374-376, 379, 381

Agoraphobia, 47, 48, 161, 228, 233-235, 239, 336

AIDS, 71, 138, 173, 286, 363, 366, 439

Air Force Surgeon General, 160

Akathisia, 89, 281, 344

Alcohol. *See* Substance abuse

Alcohol and Drug Abuse and Mental Health Administration Reorganization Act of 1992. *See* Public Law 102321

Alcoholics Anonymous, 94, 289

Alprazolam, 242, 355

Alzheimer's disease, 356-364

acetylcholinesterase (AChE) inhibitors, 362

assessment and diagnosis of, 357-360

caregivers, 363-364

causes, acetylcholine and, 361-362

causes, biological factors, 360-361

causes, histopathology and pathophysiology, 361

causes of, 360-362

causes, protective factors, 360-361

cost of, 360

course of, 359

diagnosis and prevention of progression, 357, 358

gender and, 359

graying of America and, 360

memory aids, 363

mild cognitive impairment (MCI), 357-359

prevalence and incidence of, 359-360

primary care providers, 358

societal view of senility, 358

symptoms of, 356, 359

treatment of behavioral symptoms, 362-363

treatment, cognitive and behavioral, 363

treatment of depression, 363

treatment, in nursing homes, 364

treatment, pharmacological, 362-363

treatment, psychosocial, of patients and caregivers, 363-364

American Academy of Child and Adolescent Psychiatry (AACAP), 146, 158

American Academy of Pediatrics, 149, 183

American Association of Retired Persons, 370

American Medical Association (AMA), 438

American Psychiatric Association, 5, 6, 44, 45, 145, 233, 234, 241-243, 262, 266, 369, 375, 438, 445

American Psychological Association (APA), 11, 71, 91, 140, 147, 155, 162, 166, 438, 445

American Psychological Association Task Force Criteria, 140, 155, 162, 166

Americans With Disabilities Act (ADA), 285, 446, 447

Amino acids, 36, 37

Amnesia, 237

Amphetamine salts, 146

Amphetamines, 158

Amygdala, 36, 38, 239, 240

Mental Health: A Report of the Surgeon General

- Anhedonia, 41, 42, 245, 271
- Anorexia nervosa, 47, 48, 53, 136, 167, 228, 336
- Anthony, William, 100
- Anticonvulsants, 69, 260, 266, 268
- Antidepressants, 261–266, 352–355
- Antioxidants, 361
- Antipsychotics, 271, 274, 278–280, 281, 283, 343, 362, 366, 367
- Anxiety, 40–41
 - animal model of, 52
 - anxiety disorder defined, 40
 - causes and onset of, 40
 - depression and, 253–54
- Anxiety disorders in adults, 225–226, 233–243
 - acute and post-traumatic stress disorders, 237
 - acute stress response and the brain, 238–239
 - agoraphobia, 234–235
 - anatomic and biochemical bases of, 239–240
 - causes of, 239–241
 - combined psychotherapy and pharmacotherapy, 242
 - counseling and psychotherapy for, 241, 243
 - generalized anxiety disorder, 235–236
 - neurotransmitter alterations, 240
 - obsessive-compulsive disorder, 236–237
 - occurrence and co-occurrences, 233
 - panic attack and panic disorder, 233–234
 - pharmacotherapy for, 242–243
 - psychological theories of, 240–241
 - social phobia, 235
 - specific phobias, 235
 - stressor and stress response defined, 238
 - treatment of, 241–243
 - types of, 233–237
- Anxiety disorders in children and adolescents, 160–163
 - CBT and, 162
 - generalized anxiety disorder, 160
 - obsessive-compulsive disorder and PANDAS, 162–163
 - separation anxiety disorder, 160–161
 - social phobia, 160–161
 - treatment of, 162
- Anxiety disorders in older adults, 364–365
 - benzodiazepines and, 364–365
 - buspirone and, 365
 - post-traumatic stress disorder (PTSD), 364
 - prevalence of, 364
 - treatment of, 364–365
- Anxiolytics, 69, 71, 242, 243, 365
- Asian, 81–83, 85–88, 182, 282, 289
- Asian/Pacific Islanders, 81–83, 85–88, 182, 242, 263, 282, 289
- Aspartate, 37
- Asperger's disorder, 137
- Assault, 87, 161, 230, 237
- Assertive community treatment, 80, 92, 99, 227, 280, 286, 287, 290, 290, 295, 455
- Attachment, 60, 126, 126, 130–132, 165, 254
- Attention deficit/hyperactivity disorder (ADHD), 142–150
 - associated disorders and, 144
 - causes of, 144–145
 - dopamine hypothesis, 145
 - inheritance, 145
 - MTA Study, 148–149
 - prevalence of, 144
 - psychostimulants, 146
 - symptoms of, 142–144
 - treatment, behavioral, 147–148
 - treatment, CBT, 148
 - treatment controversies, 149–150
 - treatment, multimodal, 148–149
 - treatment of, 146–150
 - treatment, pharmacological, 146–147
 - treatment, psychosocial, 147–148
 - treatment side effects, 146–147
- Attrition factors, 258, 263, 356
- Atypical antipsychotics, 69, 345
- Auditory hallucinations, 41, 150, 271

Autism, 23, 53, 129, 136, 137, 163, 164
 Autistic disorder, 270
 Avoidance, 6, 41, 82, 161, 229, 234, 235, 237,
 240, 254, 255, 273, 343
 Axons, 33, 37, 58
 Azopyrine, 243

B

Baby boomers, 368, 369
 Bandura, 57, 126, 162, 229
 Barriers to treatment, 8, 13, 18-21, 23, 55, 65,
 70, 72-73, 80, 86-88, 91-92, 138, 160,
 192, 193, 226, 244, 256, 257, 280, 294,
 296, 341, 344, 346, 348-349, 352, 367,
 374, 375, 376, 381, 408, 416, 417, 424,
 429, 453, 457
 Basal ganglia, 35, 55, 163
 Bazelon Center for Mental Health Law, 80
 Beers, 93
 Behavior therapy, 57, 66, 67, 149, 162-164
 Behavioral symptoms, 17, 174, 242, 338, 343,
 344, 357-360, 362-364, 374
 Benzodiazepines, 69, 142, 162, 242, 243, 268,
 343, 350, 364, 365, 369, 370
 Bereavement, 5, 19, 189, 230, 232, 245, 247,
 254, 335, 336, 339-341, 347, 351, 356, 379
 Biological models of the mind, 39
 Biopsychosocial model of disease, 52
 Bipolar disorder, 250, 266. *See also* Mania
 Blame, 96, 154, 158, 164, 187, 274
 Bowlby, John, 57, 59, 60, 126
 Boys Town, 177
 Brain, 6, 13, 15-17, 239-241, 453
 anxiety disorders and, 238-240
 bottomup studies of, 13
 cellular changes in, as result of human
 experience, 15
 as central focus for studies of mental health
 and illness, 13
 genes, role of, 13, 16-17
 inseparability of human experience, 15
 as mediator of mental function, 13
 as mediator of symptoms of mental illness,
 453
 mental disorders and physical changes in, 6
 physical changes in as cause of changes in
 body, 6
 prenatal factors, 16
 topdown research, 13
 Brain damage, 129, 145
 Brain, imaging of, 38-39
 Brain, neurochemical complexity of, 36-37
 aspartate, 37
 corticotropin-releasing factor (CRF), 36
 dopamine, 36, 37
 endogenous opiates, 36
 gamma amino butyric acid (GABA), 37
 glutamate, 37
 ligand-gated channel, 36-37
 neurotransmitter receptor, 36
 neurotransmitters, 36-37
 neurotransmitters as targets of medication,
 37
 norepinephrine, 37
 peptides, 37
 serotonin, 37
 substance P, 36
 Brain, plasticity of, 12, 38
 brain structure altered with learning, 38
 dual-level examination necessary, 38
 genes and, 38
 molecular and cellular alterations, 38
 as result of stress, substance abuse, and
 disease, 38
 Brain, structural complexity of, 32-37
 amygdala, 36
 axons, 33, 35
 basal ganglia, 35-36
 cellular level organization, 32-36
 cerebral cortex, 33
 as distributed information processor, 33
 frontal lobe, 33
 geographic specialization, 33-36
 gray matter, 35
 gyri, 33
 hippocampus, 36
 local damage compensated by other
 regions, 36

Mental Health: A Report of the Surgeon General

- as mediator of all human behavior, 31
- and mind, 31
- myelin, 33–35
- organization of circuits in, 33
- occipital lobe, 33
- parietal lobe, 33
- prefrontal cortex, 33
- sulci, 33
- white matter, 33–35

Bruner, Jerome, 126, 133

Bupropion, 147, 263, 264, 266, 267, 353

Buspirone, 242, 243, 244, 365

C

California Department of Mental Health, 99

Call to Action on Suicide, 4, 244

Campbell, 95, 99, 134, 141, 157, 164, 166, 439, 442, 443

Cancer diagnosis, reaction to, 52

Carbamazepine, 142, 157, 166, 268

Cardiotoxicity, 263

Caregivers, 21, 59, 60, 133, 165, 187, 188, 189, 232, 343, 356, 359, 360, 363, 373, 378–381, 405, 443, 449

Carolina Abecedarian Project, 134

Carved-in, carved-out benefits, 376–377, 421

Case, definition of, 48

Case management, 94, 99, 168, 172–174, 180, 183, 189, 193, 280, 286–288, 290, 290, 295, 375, 376, 418, 426

Case manager, 94, 95, 173, 174

Catatonia, 249, 259, 261

Causation, 10, 44, 50–52

Causation, difficulty in establishing, 51–52

Center for Mental Health Services (CMHS), 24, 80, 82, 90, 95, 107, 186, 188, 189, 261, 273, 286, 290, 290, 294, 295, 425

Center for Substance Abuse Treatment, 446

Centers for Disease Control and Prevention, 62, 159

Central nervous system, 42, 61, 129, 145, 163, 251, 278, 338, 353

Cerebral cortex, 33, 238

Chamberlin, Judi, 93–94

CHAMPUS, 192

Child abuse, 130, 132, 135, 445, 446. *See also* Abuse

Child sexual abuse, 231

Children and adolescents, in general, 17–18, 123–194

Children and adolescents, mental disorders in, 123, 136–142

anxiety disorders in. *See* Anxiety disorders in children and adolescents

assessment and difficulty of diagnosis in, 137–138

attention deficit/hyperactivity disorder, 142–150, 164

autism, 163–164

conduct disorder, 165–166

disruptive disorders, 164–166

eating disorders, 167

evaluation process, 138–139

general categories, 136–137

medications, off label use of, 141

oppositional defiant disorder (ODD), 164–165

psychopharmacology, and lack of research on medications, 140–142

psychotherapy, and lack of evidence concerning efficacy, 140

shortage of professionals, 138

substance use disorders in adolescents, 166–167

treatment strategies, 139–142

Child and Adolescent Service System Program (CASSP), 188, 189, 192

Child Behavior Checklist, 139

Child Health Insurance Program (CHIP), 183, 407, 419

Children and adolescents, 12, 16–18, 46, 48, 90, 103, 247, 250, 406, 409, 455, 457

Children and Adults with Attention Deficit Disorder (CHADD), 148

Children and Youth Intensive Case Management (CYICM), 173

Children's Services Program, 189, 191

Chlorpromazine, 68, 157, 278, 280

Cholecystokinin, 240

Chronic disability, 337

- Classical conditioning, 56, 240
- Clinical Global Improvement Scale, 156, 157
- Clinical psychologist, 138
- Clinical research volunteers, 21, 454
- Clinician bias, 85, 87, 88, 273, 288
 - overdiagnosis of schizophrenia in African Americans, 88
 - underdiagnoses, 88
- Clomipramine, 164, 242
- Clonazepam, 242
- Clonidine, 147, 166
- Clozapine, 268, 278, 280–282, 345, 367
- Code of Ethics, 438
- Coercion, 23, 457,
- Cognition, 39, 40, 43, 58, 62, 67, 137, 226, 245, 251, 269, 337, 347, 359, 362, 363
- Cognitive-behavioral therapy (CBT), 22, 57, 66, 67, 126, 140, 148, 155–158, 163, 167, 232, 241, 265, 266, 355, 356, 455
- Cognitive capacity, 337
- Cognitive decline, 341, 358
- Cognitive impairment, 43, 48, 146, 228, 260, 336, 345, 349, 354, 357–359, 363, 365, 375
- Cognitive therapy, 355, 363
- Combined services and combined treatment, 18–19, 288–289, 296, 412–413
- Community-based interventions, newer, 172
- Community Support Program, 290, 295
- Community treatment, 79, 80, 92, 99, 227, 280, 286, 287, 290, 295, 455
- Comorbid medical illness, 273
 - and depression, 244
 - and schizophrenia, 273–274
- Comorbidity, 46, 47, 63, 72, 166, 167, 228, 233, 234, 244, 267, 273, 288, 338, 340, 342, 346, 352, 354, 360, 372, 377, 406, 408
- Comprehensive care, 225, 289
- Conduct disorder, 126, 130–132, 137, 150–152, 164–166, 171, 189
- Confidentiality, 13, 20, 21, 438, 440, 447–449
- Confidentiality: ethical, legal, and policy issues, 437–449
 - case utilization review and candor, 440
 - ethical issues, 438–439
 - fostering trust, 439
 - industry changes, and for profit corporations, 437
 - more protections may be warranted, 437
 - protecting privacy, 439–440
 - reducing stigma, 439
 - research on confidentiality and treatment, 440–441
 - technological advances in information usage and storage, 437
 - values underlying confidentiality, 439–440
- Confidentiality of Individually Identifiable Health Information, 447
- Confidentiality law, 440–448
 - differs for mental health and substance abuse treatments, 448
 - disclosure, 443–445
 - disclosure to client, and child clients, 443
 - exceptions to confidentiality, 442–445
 - national standard lacking, 441
 - preemption, 447–448
 - reform proposals, 441–442
 - in research, 444–445
 - valid consent rarely defined, 442
 - waiver of confidentiality, 442
- Confidentiality of mental health information, 20–21, 437–449
 - information technology and, 21
 - informed consent and, 21
 - state and Federal laws and, 21
 - U.S. Supreme Court and, 21
- Confusional state, 249
- Consent, 21, 72, 260, 261, 440, 442–449
- Consumer advocacy, 291–293
- Consumer and family, 13, 14, 92, 96–98, 100, 101
- Consumer and family movements, 92–97
 - blame attributed to families and, 96
 - consumer groups, origins and goals, 93–94
 - consumer organizations, accomplishments of, 95–96
 - consumer roles in research, 95–96
 - consumers as employees, 95
 - deinstitutionalization and, 96
 - family advocacy, 96

Mental Health: A Report of the Surgeon General

- Federation of Families for Children's Mental Health (FFCMH), 96–97
- incorporation into other mental health services, 94
- National Alliance for the Mentally Ill (NAMI), 96
- National Mental Health Association (NMHA), 96–97
- Public Law 102-321 and, 95
- self-help groups, 94
- underrepresentation of ethnic and minority groups in, 93–94
- Consumer Bill of Rights and Responsibilities, 20, 430, 429
- Consumer run, 15, 94, 102, 290
- Contingency management, 147, 162
- Control group, 10, 71, 134, 148, 155, 156, 164, 172, 174, 175, 191, 233
- Co-occurring mental and substance use disorders
 - combined treatment of, 18–19, 288–289, 296, 412–413
 - comorbidities, 244
 - in adolescents, 166–167
 - in older adults, 368–370
 - incidence of, 15, 46
 - long-term outcome, 288
 - post-traumatic stress disorder and, 237
 - schizophrenia and, 273–274
 - shortage of services for, 455
- Coping and self-monitoring, 284
- Correlation, 51, 165
- Correlational research, 10, 51
- Corticotropin-releasing factor (CRF), 36
- Corticotropin-releasing hormone (CRH), 36, 239, 240, 242, 253
- Cortisol, 153
- Cost containment, 20, 408, 417, 419, 421, 429, 437
- Cost controls, 423
- Counseling, 138, 149, 156, 159, 169, 175, 182, 183, 189, 232, 241, 265, 269, 294, 342, 343, 364, 373, 406, 437
- Couples therapy, 65, 232
- Crisis programs, 178
- Crisis services, 12, 16, 94, 102, 159, 172, 178–179, 288, 290
- Cultural diversity and mental health services, 45, 55, 80
 - acculturation, defined, 81
 - Americans and, 88
 - barriers to treatment of minorities, 86–88
 - clinician bias, 88
 - coping and idioms of distress, 83
 - coping and religious beliefs, 82–83
 - coping and somatization and folk disorders, 83
 - coping styles of various cultural groups, 82–83
 - cost, 87–88
 - cultural competence, defined, 90
 - cultural competence in mental health practitioners, 90–91
 - culture and cultural identity, 81–82
 - diversity and demographics, 81–83
 - DSM-IV “Outline for Cultural Formulation,” 90
 - epidemiology and utilization of services, 84
 - ethnopsychopharmacology, 88–89
 - family and community as primary resources, 83–85
 - improving treatment for minority groups, 88–91
 - income status and role in mental disorders, 82
 - Indian Health Service (IHS), 90
 - linguistically and culturally competent services, 81, 225
 - metabolism, genetic and psychosocial influences, 89
 - minorities, fear of system by, 80–81
 - minorities poorly served, 80–81
 - minority-oriented services, 89–90
 - mistrust, 86–87
 - overdiagnosis of schizophrenia in African Americans, 88
 - racial or ethnic minority groups, major, Federal designation, 81
 - racist slights, microinsults, 87
 - rural mental health services, 92

stigma, 87
 treatment effectiveness across race, culture,
 largely unknown, 91
 underdiagnoses, 88
 under- and overrepresentations in treatment
 populations, 84–86
 unrecognized variations in health-seeking
 behaviors, 84
 Culturally appropriate treatment, 18, 49, 84,
 90, 181, 182, 186,
 Cyclothymia, 226, 244, 245, 251
 Cystic fibrosis, 53

D

Darwin, 60
 DAT1, 145
 Deegan, 97, 98
 Deinstitutionalization, 7, 8, 68, 79, 93, 96, 98,
 275, 286, 293, 374, 405. *See also*
 Institutionalization and
 deinstitutionalization
 Delirium, 9, 338, 358
 Delivery of state-of-the-art treatments, 22, 455
 Delusions, 41, 150, 226, 245–247, 249,
 270–272, 359, 362, 365, 367, 371
 Demographic characteristics, 405
 Dendrites, 33, 61
 Department of Health and Human Services, 23,
 232, 370, 413, 447
 Depression and other mood disorders in adults,
 226, 228, 244–269
 acute inpatient treatment, 258
 acute phase efficacy in mania, 267–268
 anxiety and depression, 253
 assessment, 245–251
 augmentation strategies, 265
 biological factors in, 251–252
 bipolar depression, treatment of, 265–266
 bipolar disorder, 246, 249, 250
 bupropion, 264
 causes, 251–257
 clinical depression, 244–246
 cognitive factors, 254–255
 complications and comorbidities, 244–245

continuation phase therapy, 261
 cyclothymia, 250–251
 diagnosis and syndrome severity, 245–251
 dysthymia, 247, 249
 electroconvulsive therapy (ECT), 258–261
 evolving views of, 252–253
 female depression, role of environment in,
 255–256
 gender and, 255–256
 heterocyclic antidepressants (HCAs), 262
 hippocampus and, 253
 learned helplessness, 254–255
 maintenance pharmacotherapy vs.
 psychotherapy, 267
 maintenance phase therapies, 261
 maintenance treatment in mania, 268
 major depressive disorder, 247–248
 medication, contributing role in, 251
 misdiagnosis of schizophrenia in African
 Americans, 249
 monoamine hypothesis, 252
 monoamine oxidase inhibitors (MAOIs),
 262, 264
 outpatient treatment, 258
 pharmacotherapies, 262–263
 pharmacotherapies, alternate, 263–265
 pharmacotherapy, psychosocial therapy,
 and multimodal therapy, 266–267
 and primary care, 269
 psychosocial and genetic factors in,
 254–257
 psychotherapy and counseling, 265
 relapse, prevention of, 267
 remission defined, 261
 selective serotonin reuptake inhibitors
 (SSRIs), 262–263, 265
 service delivery for, 269
 social and economic impact, 244
 St. John's wort, 264–265
 stressful life events, 254
 suicide, 244, 245
 temperament and personality, 255
 therapy, stages of, 257–261
 treatment, general, 257–262

- Education, 93–97, 126, 133–136, 183–185, 187–189
- Effectiveness and efficacy, 3, 10, 11, 13–15, 21, 22, 65, 67, 71, 72, 91, 94, 101, 102, 416, 418, 453
- Ego, 56, 60, 338
- Ego integrity, 60, 338
- Electroconvulsive therapy (ECT), 65, 93, 94, 250, 258–262, 266–268, 354, 355
- Elmira Prenatal/Early Infancy Project, 134
- Employers, 74, 289–294, 294, 377, 407, 418, 421
- Empowerment, 95, 99, 188, 289, 293
- Empowerment Scale, 99
- Endocrine factors, 255, 340
- Endogenous opiates, 36
- Engel, George L., 50
- Epidemiologic Catchment Area (ECA), 46–48, 228, 257, 336, 341, 348, 349, 364, 369, 406, 408
- Epidemiology, future directions for
 mental disorder, case of, defined, 48
 mental disorder, establishing threshold for, 48–49
 rates of disorder vs. measures of need, 49
 treatment, lack of standard measures of need for, 49
- Epigenetic influences, 58
- Erikson, Erik, 57, 59, 60, 126, 227, 338
- Estrogen, 275, 342, 361, 367
- Ethical Principles of Psychologists, 438, 439
- Ethnicity, 80–84, 91, 181, 182, 262, 282
- Ethnopharmacology, 282
- Ethnopsychopharmacology, 88–89
- Etiology of mental disorders, 31, 49–57
 and age, 51
 biopsychosocial factors in, 50, 52
 correlation, causation, and consequences, 51–52
 defined, 31
 of extroversion, 50
 interplay of factors in, 49
 of post-traumatic stress disorder, 50–51
 and stress, 51, 52
 stressor, defined, 51
 stress response, defined, 51
- Etiology research, 11, 31, 341
- Evidence-based interventions, 21, 454
- Evidence-based services, 22, 455
- Excess disability, 341, 343, 351, 358
- Experimental group, 10, 164, 174
- Experimental research, 10, 51
- Extra Organizational Empowerment Scale, 99
- Eyberg Child Behavior Inventory, 139
- ## F
-
- Family advocacy, 96, 98, 292
- Family Centered Intensive Case Management (FCICM) program, 174
- Family Interaction Coding Pattern, 139
- Family intervention, 158, 283
- Family preservation programs, 175
- Family support, 22, 96, 178, 188, 189, 274, 278, 364, 370, 375, 380, 455
- Family therapy, 155, 157, 167, 168, 189
- FDA Modernization Act, 141
- Fear and anxiety, 31, 36, 40, 52, 233–235, 238–240, 241
- Fear of mental health system by minority groups, 80–81, 87
- Federal Employees Health Benefit Program, 429, 458
- Federal financing, 376, 420
- Federal government, role of, in mental health issues, 81, 188, 375, 407, 415–420, 426, 438, 447
- Federation of Families for Children's Mental Health (FFCMH), 80, 96, 97, 188, 189
- Fetal alcohol syndrome, 133, 163
- Financial barriers, 20, 23, 257, 429, 457
- Fluoxetine, 147, 156, 164, 243, 262, 263, 353
- Flupenthixol, 158
- Fluvoxamine, 243, 262
- Food and Drug Administration (FDA), 10, 11, 70, 71, 141, 243, 262, 263, 268
- Fort Bragg study, 191, 193
- Fostering Individualized Assistance Program (FIAP), 174
- Freud, Anna, 127

Mental Health: A Report of the Surgeon General

Freud, Sigmund, 55, 59, 66, 124, 126, 127
Frontal lobe, 33, 354, 357
Future directions for epidemiology, 48

G

G protein-linked receptors, 37
Galton, 60
Gamma amino butyric acid (GABA), 37, 240, 242, 252
Gatekeepers, 138
Gender, 12, 14, 16, 19, 22, 39, 44, 55, 63, 81, 86, 101, 102, 153, 159, 171, 228, 235, 244, 255, 256, 263, 275, 282, 359, 426, 456. *See also* Alzheimer's disease; Depression and other mood disorders in adults; Depression and suicide in children and adolescents; Schizophrenia, demographic characteristics in; Schizophrenia in older adults
General medical service providers, 413
Generalized anxiety disorder, 40, 47, 137, 160, 161, 225, 228, 233–236, 239, 242, 243, 364
Genetic factors, 50, 127, 153, 163, 226, 237, 251, 254, 256, 276, 360
Genetics, 11, 13, 21, 39, 52, 53, 100, 129, 144, 257, 279, 453
Gestalt therapy, 67
Glia, 32
Global Burden of Disease study, 4, 411
Glucocorticoids, 239, 240, 251
Glutamate, 36, 37
Glycine, 36, 37
Gray matter, 35, 36, 239
Grief, 66, 230, 245, 254, 265, 340, 342, 351, 356
Grob, Gerald, 6, 9, 75, 78, 93
Group therapy, 65, 177, 231
Guanfacine, 147
Gyri, 33

H

Hallucinations, 41, 42, 150, 226, 245–247, 249, 269–272, 359, 365, 367
Haloperidol, 69, 164, 280, 281, 367

Harvard University, 4
Head Start, 133, 134
Health Care Financing Administration (HCFA), 45, 412, 416
Health insurance, 20, 182–185, 294, 418–421, 422, 427, 438, 457
Health insurance benefits, 70, 79, 232, 292, 407, 426–428, 455, 457
Health maintenance organization (HMO), 374, 376, 421, 422
Health Security Act, 427
Heart, 147, 238, 263, 268, 352, 355
Heterocyclic antidepressants (HCAs), 262
Hippocampus, 36, 38, 61, 239, 240, 252, 253
Hispanic Americans, 81, 85, 86, 152, 181, 186–187, 256, 282, 289, 368
Histopathology, 361
HIV, 54, 55, 62, 133, 251, 286, 288, 357
Home Based Crisis Intervention (HBCI), 179
Home-based services, 74, 140, 166, 172, 175
Homicide, 244
Hospitalization, 168–173, 286–288, 293, 339, 406, 418, 423
Human genome project, 52, 53
Human services, 22, 23, 73, 75, 133, 232, 289, 292, 295, 370, 378, 405–409, 413, 417, 438, 444, 447, 455.
Humanistic approaches, 65–67
Huntington's disease, 53, 357
Hypersomnia, 42, 247
Hyperthyroidism, 234, 250
Hypomania, 151, 153, 249, 250, 251, 266, 348
Hypothalamic-pituitary-adrenocortical (HPA) axis, 239, 252, 253
Hypothalamus, 153, 239, 253
Hypothyroidism, 247, 251, 256, 338, 357, 358

I

Id, 56
Illicit drugs, 368, 369
Imipramine, 68, 69, 156, 157, 242, 267, 362
Immune function, 337, 340
Impulsivity, 142–144, 146, 148, 229, 255
Income assistance, 292

Income, effects of, in mental health and mental illness, 19, 79, 82, 88, 99, 135, 180, 183, 189, 233, 292–294, 378, 419, 422, 427

Indemnity, 419, 421

Indian Health Service (IHS), 90

Individuals With Disabilities Education Act (IDEA), 183, 184, 188, 189

Inequities in treatment and services, 13, 20, 405, 413, 426–429, 457

Infancy, 44, 99, 131, 134, 135, 342

Infant Health and Development Program, 134

Infections, 52, 133, 163, 251, 278

Informed consent, 21, 72, 260, 261, 440, 449

Inpatient treatment, 88, 169, 171, 172, 175, 176, 258, 456

Institute of Medicine (IOM), 51, 62–64, 94, 96, 225, 231, 232, 255, 288, 339, 343, 374, 380, 425

Institutionalization and deinstitutionalization, 68, 75, 78–79, 84, 93, 96, 98

Insurance, 407, 409, 412, 413, 415–422, 424, 426–429, 438, 440, 441, 457

Insurance restriction, 426

International Classification of Diseases (ICD), 45, 83

Interneuron, 32

Interpersonal therapy, 22, 66, 125, 155, 157, 167, 261, 265–267, 353, 355–356, 455

Intervention, 132–136, 140, 155–159, 162, 164–166, 177–180, 190–192, 231, 244, 260

Invisible Children, 97

Invisible Children's Project, 184

Involuntary commitment, 23, 93, 457

IQ, 133, 134, 165, 171, 337

J

Jackson, 84

K

Kandel, 6, 57, 58, 61, 138, 240

Kaslow and Thomson, 156

Kierkegaard, 67

Knitzer, 97, 171, 187

Kraemer, 129

Kraepelin, 97, 269, 366

L

Landscape for aging, 371, 372

Language, 5, 6, 43, 50, 62, 81, 86, 124, 126, 136–138, 149, 163, 164, 269, 271, 337, 356, 357, 359, 437, 439, 441

Late onset of mental disorders, 244, 347, 350–352, 366

Late life, 17–19, 23, 104, 335, 339–341, 346, 348, 349, 354, 364, 365, 367, 370

Late-onset depression, 347, 350–352

Law enforcement, 133, 191, 445, 446

Learned helplessness, 254

Lethality, 263

Level of evidence, 10, 11, 142, 159

Lewinsohn, 152, 154, 156

Lifespan, 15, 102

Lifespan approach, 12

Ligand, 36

Limbic system, 163, 238, 239

Limitations in service and insurance benefits, 90, 269, 288, 295, 413, 417–423, 425–427

Linguistically and culturally competent services, 81, 225

Lithium, 68, 69, 142, 147, 157, 158, 166, 249, 260, 265–268

Living With Children, 166

Locus coeruleus, 37

Lorazepam, 242

Lorenz, Konrad, 60

M

Madness Network News, 93

Magnetic Resonance Imaging (MRI), 14, 38, 100, 240, 347, 351

Maintenance pharmacotherapy, 261, 267

Malpractice, 266

Managed behavioral health care organizations (MBHOs), 421

Managed care, 13, 19, 20, 23, 85, 94, 169, 181, 183–185, 268, 282, 290, 336, 370, 371,

Mental Health: A Report of the Surgeon General

- 373, 375-378, 405, 417, 420-430, 443, 455, 458
- Managed Care Consortium, 291
- Mania, 42, 43, 69, 151, 157, 244-246, 249, 251, 252, 258-261, 266-268, 348
- Mann, Horace, 78, 153, 246
- MECA Study, 124
- Medicaid, 19, 74, 79, 85, 135, 182-186, 294, 360, 371, 374-377, 381, 407-409, 415-420, 422, 458
- Medicare, 19, 74, 79, 294, 360, 369, 371, 375-377, 381, 407, 413, 415-420, 422, 458
- Memory, 31, 33, 36, 38, 337-338, 341, 355-359, 362-367
- Mendelian disorders, 53
- Mendelian transmission, 53
- Menninger Clinic, 177
- Mental disorders, 4-5, 20, 39-40
 - brain as mediator in, 39
 - characterized by, 39
 - continuum of conditions, 39
 - cost to the Nation, 20
 - cultural influence and, 39
 - defined, 5
 - demographics and, 39
 - prevalence of, 20
 - prevention of, 233
 - societal burden compared, 3-4
- Mental health, 3-6
 - defined, 4-5, 227
 - dynamic and ever changing, 16
 - inseparable from physical health, 5-6
 - success dependent on, 4-5
 - vs. somatic health, 6
- Mental health and mental illness
 - biological influences on, 52-55
 - brain and scientific research, 100
 - causes of, 225
 - consumer and family movements, 101-102
 - integrative science of, 57
 - Kandel and, 57
 - lifespan and, 102-104
 - organization and financing of care, 101
 - personality traits, 227-230
 - psychosocial influences on, 55-57
 - treatments and integrative neuroscience, 100-101
- Mental Health Parity Act, 427, 428
- Mental health promotion and illness prevention, 22, 454
- Mental illness
 - in children and adolescents, 46, 48
 - cluster of signs and symptoms and, 45
 - co-occurring disorders in adults, 46
 - cost to the individual, 227
 - cost to society, 226
 - costs, 49, 225-227, 411-417
 - diagnosis of, 43-45
 - disorder vs. disease, 44
 - epidemiology, defined, 45
 - epidemiology of, 45-49
 - in older adults, 48
 - incidence, defined, 45
 - inseparable from physical illness, 5-6
 - prevalence, defined, 45
 - serious emotional disturbance (SED) in children and adolescents, 46
 - serious mental illness (SMI) in adults, 46
 - severe and persistent mental illness (SPMI) in adults, 46
 - symptoms and signs of, 39-40
- Mental retardation, 23, 130
- Meta-analysis, 11, 167, 168, 175, 266, 355
- Metabolism, 88, 89, 154, 238, 263, 265, 277, 280, 283, 342, 344
- Methodology for Epidemiology of Mental Disorders in Children and Adolescents (MECA) study, 48, 123, 124
- Methylphenidate, 145-147, 149, 150, 157, 166
- Mild cognitive impairment (MCI), 357, 358
- Millon Adolescent Personality Inventory (MAPI), 138
- Mini Mental Status Exam, 359
- Minnesota Multiphasic Personality Inventory (MMPI), 139
- Minority groups, 23, 31, 45, 73, 80-84, 86-88, 90, 186, 233, 257, 289, 456. *See also* African Americans; Asian/Pacific Islanders; Hispanic Americans; Native Americans/American Indians/Alaska

Natives/Native Hawaiians (American Indians)
 Mirtazapine, 243, 263
 Modeling, 162, 166
 Molecular and cellular biology, 13, 100
 Molecular genetics, 11, 13, 21, 39, 100, 453
 Monoamine hypothesis, 252, 253
 Monoamine oxidase inhibitors (MAOIs), 69, 167, 243, 262, 264–266
 Moral hazard, 20, 420, 421, 423, 426, 429
 Motor behavior, 33, 271
 Movement disorders, 343
 Multimodal therapies, 139, 243
 Multimodal Treatment (MTA) Study, 148, 150
 Multisystemic therapy (MST), 166, 172, 175
 Myelin, 33

N

Naltrexone, 370
 National Advisory Mental Health Council (NAMHC), 46, 424, 428, 456
 National Alliance for the Mentally Ill (NAMI), 80, 96, 188, 189, 292, 428, 438
 National Association of Mental Patients, 94
 National Comorbidity Survey (NCS), 46, 47, 167, 228, 364, 406, 408
 National Household Survey on Drug Abuse, 369
 National Institute of Mental Health (NIMH), 24, 32, 52, 53, 54, 61, 84, 95, 129, 190, 139, 146, 148, 157, 163, 237, 251, 255, 257, 259, 260, 280, 290, 342, 354, 409
 National Institutes of Health (NIH), 24, 71, 144, 259, 260, 340, 341, 346, 348, 349, 354
 National Mental Health Association (NMHA), 78–80, 93, 96, 97, 133, 183, 189, 291
 National Mental Health Consumers' Association, 94
 National Research Council, 181, 232
 Native Americans, 86, 90, 288
 Native Americans/American Indians/Alaska Natives/Native Hawaiians (American Indians), 81, 86, 87, 90, 153, 191, 288
 Naturalistic studies, 354

Nature and nurture, 12, 60, 61, 136
 Nefazodone, 243, 263, 267, 353
 Negative reinforcement, 56, 240
 Nerve cells, 13, 32, 33, 37, 100
 Neurobiology, 238
 Neurocircuits, 239
 Neurodevelopmental disruption, 276
 Neurodevelopmental theory of schizophrenia, 278
 Neuroendocrine systems, 61, 153
 Neuroimaging, 239, 240, 252, 357
 Neuroleptic, 68, 69, 147, 158, 268, 272, 344, 345, 366, 367
 Neuronal activity, 33
 Neurons, 13, 32–38, 50, 54, 55, 58, 61, 68, 100, 163, 238, 242, 252, 253, 262, 361, 362
 Neuroscience of mental health, 31, 32
 Neuroticism, 229, 255
 Neurotransmitter receptors, 33, 36–38, 50, 68–70, 262–263, 277, 280
 Neurotransmitters, 33, 36, 37, 68, 239, 240, 252, 361
 NIMH Diagnostic Interview, 139
 Norepinephrine, 36, 37, 70, 238–240, 252, 263, 264
 Nortriptyline, 353, 354, 356
 Nursing, 365, 370–372, 374–376, 406, 413, 417
 Nursing homes, 19, 71, 74, 79, 83, 336, 342, 343, 350, 351, 361, 364, 365, 370–372, 374–376, 381, 406, 413, 417

O

Obsessive-compulsive disorder (OCD), 55, 236–237
 relationship to anxiety, 40–41
 Occipital lobe, 33
 Off-label usage, 141, 262
 Office of the Surgeon General, 23, 342
 Older adults
 alcohol and substance use disorders in, 368–370

Mental Health: A Report of the Surgeon General

anxiety disorders in. *See* Anxiety disorders in older adults
assessment and diagnosis, 340–341
demographics of the near future, and, 19
depression and suicide in. *See* Depression and mood disorders in older adults
interventions for, 19
mental disorders in, 19, 340–346
prevention, 341–343
prevention of depression and suicide, 342
prevention of excess disability, 343
prevention of premature institutionalization, 343
prevention, treatment related, 342–343
primary care, 341
primary prevention, 342
schizophrenia. *See* schizophrenia in older adults
treatment for mental disorders, 343–346
Older adults and mental health, 336–340
change and human potential, 338–339
cognitive capacity, 337–338
coping with loss and bereavement, 339–340
normal life-cycle tasks, 337
Omnibus Budget Reconciliation Act, 364, 374, 375
On Our Own, 93
Operant conditioning, 56, 57, 166
Oppositional defiant disorder (ODD), 137, 147, 148, 164, 166
Organizational Empowerment Scale, 99
Outpatient treatment, 23, 78, 84–87, 168, 169, 180, 189, 192, 258, 287, 456, 457
Over-the-counter medication, 353, 368
Overdose, 158, 262, 263

P

Panic attacks, 40, 161, 233–236, 239, 241, 243
Panic disorder, 4, 46–48, 53, 161, 225, 228, 233, 234, 236, 237, 239, 241–243, 257, 336, 364, 456
Paranoia, 41, 273, 366
Parent Therapist Program, 171

Parietal lobe, 33
Parity, 20, 96, 377, 405, 426–429, 458
Parkinsonism, 89, 281, 344
Parkinson's disease, 36, 350, 357
Paroxetine, 156, 243, 262, 353, 362
Partial hospitalization/day treatment, 169
Pathophysiology, 253, 350, 361
Patient Bill of Rights, 423
Patient Outcomes Research Team (PORT), 280, 283, 286, 425
Pavlov, Ivan, 56, 125
Pemoline, 146
Peptides, 36
Perception, 7, 40, 41, 83, 88, 158, 162, 167, 180, 240, 255, 269, 271, 368
Personal Empowerment Scale, 99
Personality disorders, 44, 65, 130, 167, 230, 244, 256, 258
Personality, theories of, 55–57, 227–229, 243, 246, 255
Pharmacodynamics, 282, 344, 345, 353
Pharmacokinetics, 140, 242, 282, 345, 368
Pharmacological therapy, 226
Pharmacology, 141
Pharmacotherapy, 68, 70, 71, 89, 139, 157, 167, 226, 241–243, 257, 259, 261, 263, 265–268, 279, 280, 283, 340, 343, 348, 350, 352, 353, 356, 358, 363, 370
Phenobarbital, 158
Phobia, 40, 47, 48, 129, 160–162, 225, 228, 232–235, 238–239, 240, 242, 243, 246, 336
Phobic anxiety, 364
Physical activities, 232
Physical development, 58
Physical health, 5, 6, 71, 128, 225, 230, 274, 348, 351, 355, 379, 380, 448. *See also* Somatic health
Piaget, Jean, 57, 59, 125
Pierce, C. M., 87
Pinel, Philippe, 78
Pituitary gland, 153, 239
Placebo effect, 10, 65, 70, 71, 88, 89, 147, 156–158, 162, 164, 166, 258, 261–265, 267, 280, 352, 354–356, 362
Planning Board, 24

Point-of-service plan (POS), 421, 422
 Policy activity, 407
 Polypharmacy, 265, 342, 344, 345, 377
 Porter, 97
 Positive reinforcement, 56, 162
 Positron emission tomography (PET) scan, 38, 240
 Postsynaptic neuron, 33, 36
 Post-traumatic stress disorder (PTSD), 4, 40, 41, 47, 50, 51, 61, 86, 132, 137, 158, 225, 228, 230–233, 237, 239, 240, 242, 243, 253, 340, 364
 Preemption, 447, 448
 Preferred provider organization (PPO), 421, 422
 Prefrontal cortex, 33, 272
 President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry, 423, 425, 430
 President's Commission on Mental Health, 45, 93
 Prevention of mental disorders, 62–64, 234
 Primary care, 18, 19, 49, 73, 75, 90, 92, 193, 233, 263, 269, 285, 341, 342, 346, 348–351, 356, 358, 371–373, 376, 378, 405, 406, 416, 421, 425, 455, 457
 Primary Mental Health Project (PMHP), 135, 137
 Privacy, 13, 20, 21, 437–441, 445–449
 Privacy Act of 1974, 446
 Privilege, 437, 447, 448
Probably Efficacious Psychosocial Interventions, 140
 Problem-solving capacity, 17, 157, 158, 189, 272, 278, 337, 355, 356, 363
 Productivity, 4, 13, 18, 49, 100, 226, 244, 257, 271, 360, 411, 413
 Project ReEducation (ReEd), 170
 Protective factors, 22, 62–64, 244, 274, 342, 361, 367
 Providers of mental health services, 421–424, 428–430, 455–457
 Psychiatric nosology, 49
 Psychoanalysis, 56, 66
 Psychodynamic theories, 55, 56, 240
 Psychodynamic therapy, 66, 356

Psychoeducation, 22, 148, 233, 258, 363, 364, 455
 Psychological development, 59, 230
 Psychopharmacologic treatments, 15
 Psychosis, 4, 7, 9, 40–43, 47, 54, 68, 69, 79, 146, 228, 254, 259, 274, 354, 356, 359, 374
 Psychosocial risk factors, 63, 130, 252
 Psychosocial treatments, 78, 141, 147, 148, 166, 226, 257, 266, 282, 283, 345, 355
 Psychotherapy, 65–67, 167, 168, 177, 241, 243, 257, 258, 260, 265–267, 353–356
 Public health model, 3
 Public Law 102-331, 95, 190

Q

Quality and consumers' rights, 430
 Quality assessment, 425

R

Racial and ethnic minorities, 39, 55, 67, 73, 80–82, 84–90, 94. *See also* African Americans; Asian/Pacific Islanders; Hispanic Americans; Native Americans/American Indians/Alaska Natives/Native Hawaiians (American Indians)
 Randomized controlled trial, 10, 133, 189, 233
 Range of treatments, 13, 15, 21, 64, 65, 102, 453
 Rape, 50, 230, 237, 256
 Raphe nuclei, 37
Reaching Across, 94
 Recovery, 12, 14, 15, 18, 19, 22, 32, 55, 80, 92, 97–102, 128, 137, 154, 227, 261, 274, 275, 279, 280, 283, 284, 288–290, 349, 350, 353, 354, 366, 455
Reducing Risks for Mental Disorders, 62
 Rehabilitation services, 79, 284, 286, 287, 293, 375, 406, 418
 Relapse, 243, 259, 261, 265–268, 274, 278, 281, 283–285, 350, 353–356, 370

Mental Health: A Report of the Surgeon General

Remission, 71, 156, 161, 226, 249, 258, 261, 274, 283, 284, 349, 350, 353, 354, 356, 366
Report's principal recommendation, 13, 21
Research methods, 10
Research volunteers, 21, 454
Rett's disorder, 137
Risk factors, 16, 17, 22, 51, 53, 55, 57, 63, 64, 103, 128–133, 136, 145, 151–158, 161, 165, 170, 175, 187, 193, 231, 241, 244, 252, 256, 278, 293, 336, 340–345, 347, 350–352, 357, 361, 368, 370, 378
Risk factors and prevention in childhood and adolescent mental health, 129–136
Robert Wood Johnson Foundation, 190, 191, 289, 293, 295, 409
Rogers, Carl, 67
Residential treatment center (RTC), 170, 171

S

Social/health maintenance organization (S/HMO), 374

Schizo-affective disorder, 250, 270

Schizophrenia, 41–42, 227–228, 270–286, 365–367. *See also* Schizophrenia, demographic characteristics in; Schizophrenia in older adults; Schizophrenia, treatment of
brain abnormalities in, 276–279
causes, 276–279
comorbid medical illness and, 273–274
coping and self-monitoring, 284–285
diagnosis and cultural variations, 272–273
drug treatment of, 279–283
DSM-IV diagnostic criteria for, 272–273
epidemiology of, 273–274
genetic relationships in, 276
long-term outcomes in, 273–276, 284–285
natural history of, 274–276
onset of, 75–76
rehabilitation in, 274–275, 283–285
risk factors for, 276–278
services for, 279, 283–285, 286
symptoms and signs of, 41–42, 269–272, 276–278

Schizophrenia, demographic characteristics in
age, 275–276
culture, 272–273
gender, 275–276, 282
race, 272–273, 280–283
sociocultural status, 278

Schizophrenia in older adults, 365–367
causes of late-onset schizophrenia, 366–367
epidemiology of, 365
gender in, 367
natural history of, 366
treatment, 366, 367

Schizophrenia Patient Outcome Research Team, 88

Schizophrenia, treatment of, 279–285
ethnopsychopharmacology, 282–283
family intervention, 283
pharmacotherapy, 280–282
psychosocial, 279, 283–285
psychotherapy, 283

Schizophrenics Anonymous, 94

Schizophreniform disorder, 250

School system, 75, 169, 180, 409

Science base, 9, 21, 453

Sedatives, 237, 242

Seizures, 258–260, 264, 281, 353–354

Selective serotonin reuptake inhibitors (SSRIs), 69, 80, 89, 141, 147, 156–158, 162–164, 167, 239, 242–243, 252, 262–267, 343, 353

Self-efficacy, 189, 190, 229, 241

Self-esteem, 4, 6, 42, 94, 97, 131, 137, 170, 172, 177, 225, 228, 229, 237, 250, 285, 290, 339, 379

Self-help, 14–16, 92–97, 99, 101, 102, 289–292, 336, 340, 370, 378–380, 406, 408

Self-medication, 167

Selye, Hans, 253

Separation anxiety disorder, 12, 16, 103, 137, 160–162, 234

Serious emotional disturbance, 172, 180, 184, 185, 190, 191

Serious mental illness (SMI), 46, 48

- Serotonergic, 153, 265
- Sertraline, 243, 262, 263, 353
- Services interventions for children and adolescents, 168–179
 - case management, 172–175
 - Children and Youth Intensive Care Management (CYICM), 173
 - crisis services, 178–179
 - Family Centered Intensive Care Management (FCICM), 174
 - Family preservation programs, 175
 - Fostering Individualized Assistance Program (FIAP), 174
 - home-based services, 175–176
 - inpatient treatment, 171–172
 - multisystemic therapy (MST), 172, 175–176
 - newer community-based interventions, 172–178
 - outpatient treatment, 168–169
 - Parent Therapist Program, 171
 - partial hospitalization/day treatment, 169
 - Project ReEducation (ReEd), 170–171
 - residential treatment centers (RTCs), 169–170
 - serious emotional disturbance, defined, 172
 - therapeutic foster care, 176–177
 - team approaches, 174–175
 - therapeutic group homes, 177–178
 - treatment interventions, 168–172
- Services, mental health, including service delivery and service system: general, 73–80
 - barriers to accessibility, 21
 - care settings, 74
 - community mental health movement, 79
 - community support movement, 80
 - de facto mental health system, four sectors of, 73
 - dementia, 78
 - and dual policies of community care and deinstitutionalization, 79
 - financing of, 73–74
 - Grob, Gerald N., 75
 - history of, in U.S., 75–80
 - hybridization of system complicates service to the most needy, 80
 - linguistically and culturally competent services, 81, 225
 - majority with diagnosable disorder do not receive treatment, 75
 - mental health services, in general, 73–80
 - mental hygiene movement, 78
 - moral treatment movement, 75–78
 - patterns of use, 75
 - recovery, 80
 - state care acts, 78
- Services, mental health, including service delivery and service system: services and providers, 455–458
 - coercion, 457
 - delivery of state of the art treatments must be ensured, 455–456
 - entry into treatment must be facilitated, 457
 - financial barriers to treatment must be reduced, 457–458
 - first-line contacts, 457
 - gap between knowledge and actual practice, 456
 - geographical shortages, 455
 - inequity of coverage for mental and somatic illnesses, 457
 - justice systems, 457
 - new strategies needed, 456
 - respectful, evidence based, and reimbursable care must be ensured, 458
 - services and providers must be guaranteed, 455
 - shortages in cognitive behavioral and interpersonal therapy fields, 455
 - short supply of certain providers, services, 22, 455
 - treatment must be tailored to age, gender, race, and culture, 456
- Services, mental health, including service delivery and service system: organization and financing of, 14, 19–20, 405–430
 - cost containment policies, 20

Mental Health: A Report of the Surgeon General

- discriminatory policies in mental health financing, 20
- financial barriers to, 20
- insurance financing in, 20
- managed care, 20
- use of by U.S. population, 19
- Services, mental health, including service delivery and service system: financing and managing, 418–426
 - coverage policy, fairness in, 420
 - goals for mental health coverage, 418
 - history of financing and roots of inequality, 418
 - insurance coverage patterns, 418–419
 - lifetime limits for somatic vs. mental illness, 420
 - limitations on coverage, 418
 - moral hazard and adverse selection, 420
 - traditional insurance and dynamics of cost containment, 419–420
- Services, mental health, including service delivery and service system: managed care, 420–423
 - access, measurement system of, needed, 424
 - access to services, impact on, 424
 - and regulation, 423
 - carve-out managed behavioral health care, 421
 - cost controls in managed care, 423
 - coverage, percentages of, 422
 - health maintenance organizations (HMOs), 421
 - managed behavioral health care organizations (MBHOs), 421
 - managed care effects on service access and quality, 423–424
 - managed care plans, major types, 421
 - payer carve-outs and health plan subcontracts, 421
 - point-of-service plans (POS), 421
 - preferred provider organizations (PPOs), 421
 - quality assessment and quality indicators, 425
 - quality of care, impact on, 424–426
 - quality of care not provided incentives, 425
- Services, mental health, including service delivery and service system: mental health service system in the U.S., 405–411
 - de facto mental health service system, four components of, 405–406
 - patterns of use, 408–409
 - public and private sectors, defined, 407–408
 - school system and, 409
 - structure of U.S. service system, 405–406
 - substantial majority of adults do not receive treatment, 408
- Services, mental health, including service delivery and service system: parity, 426–428
 - benefit restrictions and, 426–427
 - gap widening between somatic and mental coverage, 427
 - legislative trends affecting, 427–428
 - Mental Health Parity Act, 427–428
 - minimal costs of parity laws, 428
 - state efforts for, 428
 - toward parity in mental health coverage, 426–428
- Services, mental health, including service delivery and service system: service delivery for adults, 285–289
 - assertive community treatment, 286–287
 - case management, 286
 - comorbidity and, 288–289
 - for substance abuse and severe mental illness, 288–289
 - inpatient hospitalization and community alternatives for crisis care, 287–288
 - intervention for stressful life events, 232–233
 - overrepresentation of minorities in inpatient units, 288
 - psychosocial rehabilitation services, 287
 - recovery and, 288
 - substance abuse and, 288
- Services, mental health, including service delivery and service system: supports and other services for adults, 289–295
 - consumer advocacy, 291

- consumer-operated programs, 290–291
- consumer self-help, 289–290
- discrimination against the mentally ill and, 292
- family advocacy, 292
- family self-help, 291–292
- health coverage and barriers to treatment, 294
- housing, 292–293
- human services, 292–294
- income, education, and employment, 293–294
- integrating service systems, 295
- Services, mental health, including service delivery and service system: service delivery and supports for children and adolescents, 179–193
 - Child and Adolescent Service System Program (CASSP), 190–191
 - Children's Services Program (CSP), 191
 - culturally appropriate social support services, 186–187
 - effectiveness of systems of care, 191–193
 - families, redefinition of and new roles for, 188
 - family support, 188–189
 - family support groups, 189–190
 - Fort Bragg study, 191–192
 - integrated system model, 190–191
 - practical support, 190
 - private sector, 182–183
 - public sector, 183–184
 - public sector, managed care in, 185–186
 - Robert Wood Johnson Foundation, 190, 191, 289, 293, 295, 409
 - service systems and financing, 182–186
 - Stark County study, 192–193
 - support and assistance for families, 187–190
 - utilization, 179–182
 - utilization and culture, 181–182
 - utilization and early termination of treatment, 180
 - utilization and poverty, 181
 - utilization in relation to need, 180
 - Wraparound Milwaukee and, 185–186
- Services, mental health, including service delivery and service system: service delivery for older adults, 370–378
 - adult day care centers and community care settings, 373–374
 - carved-in mental health services for older adults, 376–377
 - deinstitutionalization, 374
 - demographics of residence and, 370
 - ethnic diversity and, 371
 - financing services for older adults, 376
 - for severe and persistent mental disorders (SPMDs), 374–376
 - home vs. nursing home, 372–374
 - increased role of managed care, 376
 - Medicaid and, 376
 - nursing homes ill equipped to treat mental disorders, 374
 - outcomes under managed care, 377–378
 - preadmission screening, 374
 - primary care poorly equipped to treat chronic mental disorders, 372–373
 - public policy and managed care and, 370–371
 - research needed on cost-effective models for treatment, 376
 - service settings and the *New Landscape for Aging*, 371–376
 - setting, role of, in independent functioning, 372
- Services, mental health, including service delivery and service system: supports and other services for older adults, 378–380
 - abuse of older people and, 380
 - communities and social services, 380–381
 - education and health promotion, 379
 - families and caregivers, 379–380
 - support and self-help groups, 378–379
 - support for caregivers crucial, 378
- Services demonstration projects
 - brief history of, 290
 - Child and Adolescent Service System Program (CASSP), 190
 - Children's Services Program, 190–191
 - Fort Bragg study, 191–192

Mental Health: A Report of the Surgeon General

- Robert Wood Johnson Foundation, 190,
191, 289, 293, 295, 409
- Stark County study, 192–193
- Severe and persistent mental disorder (SPMD),
374, 375, 377, 378
- Severe and persistent mental illness (SPMI),
79, 289, 295, 415, 419
- Sex, 43, 56, 60, 133, 135, 151, 176, 231, 236,
255–257. *See also* Gender
- Sexual abuse, 231, 254–256
- Sexual orientation, 22, 81, 155, 442, 456
- Side effects, 39, 68, 70, 72, 89, 141, 146, 147,
156, 163, 164, 166, 226, 243, 257, 258,
262–263, 268, 271, 272, 280–282,
342–345, 352, 353, 355, 365, 367
- Skinner, B. F., 56, 125
- Sleep, 42–44, 150, 153, 245, 246, 249–253,
263, 271, 346, 349, 350, 355, 364, 365
- Sleep disturbances, 245, 350
- Social factors, 13, 47, 48, 50–52, 100, 253,
274, 278
- Social phobia, 129, 160, 161, 228, 233–236,
242, 243, 336
- Social learning theory, 56, 57, 125
- Social portfolio, 379
- Social status, role of in mental health, 55,
81–82, 84, 91
- Social support services, 181, 186
- Sociopathy, 229
- Somatic health, 6, 232–234, 272–275, 286,
427. *See also* Physical health
- Somatization disorder, 230
- Somatoform disorders, 44
- Specialty mental health providers, 14, 101, 413
- Specific phobia, 233–235
- Spending for mental health services, 12, 19, 49,
174, 249, 405, 411–417, 429
- Spirituality, role of, in mental health, 81, 82,
98, 99, 225, 232
- St. John's wort, 70, 264–265
- Stark County study, 192
- State mental health agencies and efforts, 95,
96, 291, 417, 419, 442, 446–448
- State-of-the-art treatments, 22, 455
- Stigma, 3, 6–9, 12, 14, 16, 20–22, 73, 80, 84,
85, 87, 92, 96, 101, 103, 160, 180, 186,
188, 226, 227, 244, 257, 289, 291–294,
346, 349, 376, 379, 424, 429, 439, 440,
448, 449, 453, 454
- Stimulants, 68, 69, 142, 145–150, 369
- Stress disorder, 4, 40, 41, 47, 50, 61, 86, 132,
137, 158, 225, 228, 230–233, 237, 239,
240, 242, 243, 253, 340, 364
- Substance abuse, 150–152, 154, 155, 166,
231–234, 286–289, 368–370, 408, 412,
413, 422, 424, 427–430, 437, 438, 440,
441, 445–449, 455
- Substance abuse laws, 445, 446
- Substance P, 36
- Substance-induced events, 233
- Substantia nigra, 37
- Suicide, 4, 5, 18, 19, 52, 86, 136, 150,
152–160, 165, 167, 170, 226, 232–233,
244, 246, 247, 256, 259, 268, 272–274,
288, 336, 339–342, 347, 349–352, 354,
379
- Suicide prevention, 159, 160, 244, 342, 351
- Sulci, 33
- Superego, 56, 229
- Support groups, 189, 232, 292, 356, 378, 380
- Supportive therapy, 158
- Supreme Court, U.S., 21, 437, 439, 445, 448,
449
- Surgeon General, U.S., 4, 23, 24, 160, 244, 342
- Synapses, 33, 36, 38–39, 50, 58, 61, 69, 262
-
- ## T
- Tardive dyskinesia, 147, 268, 281, 282, 344,
345, 367
- Team approaches, 174
- Temperament, 12, 31, 57, 64, 125, 125, 127,
129–132, 255
- Temporal lobe, 277, 347, 362
- Therapeutic foster care, 171, 172, 176–178,
184
- Therapeutic group homes, 172, 177, 178
- They Help Each Other Spiritually (THEOS),
379
- Tourette's disorder, 129, 137, 236
- Trauma, 18, 51, 52, 130, 159, 161, 170, 225,
230, 231, 237, 254, 256, 289

Treatment for children and adolescents, 155–160, 168

Treatment, in general, 64–73

- attitudinal barriers, 73
- barriers to seeking help, 72–73
- behavior therapy, 66–67
- cognitive-behavioral therapy, 67
- complementary and alternative treatments, 70
- demographic barriers, 73
- efficacy-effectiveness gap, 72
- existential, experiential, or Gestalt therapy, 67
- failure to seek, due to stigma, 8
- financial barriers, 73
- Freud and psychoanalysis, 66
- group psychotherapy, 65
- humanistic therapy, 67
- informal social supports now preferred, 8
- interpersonal therapy, 66
- mechanism of action, defined, 68–70
- neurotransmitter function, 68–69
- organizational barriers, 73
- pharmacological therapies, 68–70
- placebo and, 65, 70–71
- psychodynamic therapy, 66
- psychotherapy, defined, 65
- rational drug design, 68
- tailored treatment, 22–23

Treatment interventions, 19, 128, 139, 140, 168, 176, 381

Treatment systems, 6

Tricyclic antidepressants (TCAs), 69, 89, 142, 147, 156, 158, 162, 167, 242, 243, 262–265, 267, 352, 353

Trust, 21, 60, 87, 91, 437, 439, 449

Twins, 54, 61, 63, 162, 163, 165, 256, 276

U

U.S. Office of Technology Assessment, 180

Unclaimed Children, 96

Uncontrolled studies, 10, 164, 169–172, 174, 177–179, 191, 268

Undertreatment, 257, 348, 423, 426, 458

Unemployment, 64, 272, 285, 292–294

Unipolar depression, 267, 353, 354

V

Valproate, 142, 157

Vascular, 352, 354, 358

Venlafaxine, 243, 263, 267, 353

Ventral tegmental area, 37

Verapamil, 268

Violence, 7, 8, 64, 130, 165, 231, 232, 288, 439

Visual hallucinations, 249, 271

Vitamin E, 342, 357, 360, 361

Vocational issues and services, 79, 80, 99, 226–227, 235, 275, 278–279, 283–286, 287, 289, 294, 406

Volunteers, 21, 454

W

Waiver of confidentiality, 442, 443

Watson, J. B., 56, 125

Well-Being Project, 99

Well-Established Psychosocial Interventions, 140

White matter, 35, 352

World Health Organization, 4, 45, 284, 411

World Bank, 4, 411

Wraparound process, 173, 174, 179, 183, 185–186, 455

Wraparound Milwaukee, 185–186

Y

Youth Emergency Services (YES), 179, 438